• Immunovant director Atul Pande sold 1,500 shares on July 24, 2026 at USD 39.8.
• The sale followed the exercise of stock options for 1,500 shares at USD 8.43.
• Directly held stake stood at 116,731 shares after the transactions.
• The filing also reported 20,000 shares held indirectly through a trust.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001643071-26-000007), on July 24, 2026, and is solely responsible for the information contained therein.